Structurally variable stents
Summary by NHIP
Variable Pattern Drug-Eluting Stent
The tubular stent features a longitudinal base with distinct open and closed cell patterns joined by undulating articulations. A surface coating applies two layers containing a restenosis-inhibiting drug, with higher drug concentration and layer thickness at the ends than the mid-portion, all under ten microns thick.
Claim Score by NHIP
Abstract
The stent has at least two different patterns along its longitudinal length such as a closed cell and an open cell design. The stent is made from nickel/titanium, titanium, stainless steel or a noble metal. The different patterns are joined by varying articulations including a W-pattern and S-pattern. The stent has at least two coatings over the base structure, the coating depth not exceeding ten microns.

Term
Term ended
Expired 15 June 2022, 4.3 years ago.
- Priority and filed
- Granted
- Expired
- Today
9 claims: 1 independent, 8 dependent
- 1Broadest claimClaim Score 51, average(NHIP)A tubular stent comprising:a longitudinal cylindrical base structure having a first end portion, a second end portion, and a mid-portion interposed between the first and second end portions, the first and second end portions having a first pattern and the mid portion having a second pattern different from the first pattern, the second pattern including a plurality of articulations, a plurality of linear strut members connecting the mid portion to the first and second end portions, wherein the mid portion includes a plurality of articulations;and a surface coating having at least two layers coating the longitudinal cylindrical base structure, wherein the surface coating includes a drug inhibiting restenosis, with the drug having a higher concentration at the first and second end portions than at the mid portion.
37 paragraphs in 4 sections, as filed
BACKGROUND OF THE INVENTION
This invention relates to stents used to support arterial and venous conduits in the human body. More particularly, it refers to a tubular stent having a non-uniform structure along its longitudinal length to provide good flexibility and radial strength.
There are four major classes of stents employed in the prior art. These four major classes of stents are described as follows: <ul id="ul0001" list-style="none"><li id="ul0001-0001" num="0003">1. Coil Stents are made from a single wire. The wire is bent in various ways and formed into a stent. Examples of this type of stent are those shown in U.S. Pat. Nos. 4,969,458; 4,681,110 and 5,824,056.</li><li id="ul0001-0002" num="0004">2. Slotted Tube Stents are laser cut using a tube of either stainless steel, nickel/titanium alloy (NITINOL®), titanium or any other suitable materials. These designs are preprogrammed into a machine language and a laser is used to cut the programs. These stents have a uniform design and a uniform thickness from the beginning to the end of the stent. In other words, the same segment is repeated from one end of the stent to the other. Examples of this type of stent are described in U.S. Pat. Nos. 4,733,665; 4,739,762; 4,776,337 and 4,793,348.</li><li id="ul0001-0003" num="0005">3. Self Expanding Stents are usually braided or knitted with multiple wire filaments such that they have a lower profile when stretched and they expand from a lower profile to a higher profile when unconstrained in the body. These stents are called self-expanding stents and are described in U.S. Pat. No. 4,655,771.</li><li id="ul0001-0004" num="0006">4. Hybrid Stents are similar to slotted tube stents except that they do not have a closed cell structure but have an open cellular structure with flexible interconnections between each segment of the design. These interconnections provide the flexibility while the segments provide the radial strength and other important properties of the stent. Examples of this stent are described in U.S. Pat. Nos. 5,514,154; 5,562,728; 5,649,952 and 5,725,572.</li></ul>
In use, each of the four classes of stents described above are coated as described in various patents as follows: <ul id="ul0002" list-style="none"><li id="ul0002-0001" num="0008">1. U.S. Pat. No. 5,759,174, describes a balloon that has a radiopaque segment attached to one of the longitudinal ends of the balloon. When the balloon is inflated, the stent is pressed against the ends of the artery and this indicates the center portion of the dilated stenosis. The external radiopaque marker band is typically made from a dense radiopaque metal such as tantalum, gold, platinum or an alloy of those dense metals.</li><li id="ul0002-0002" num="0009">2. U.S. Pat. No. 5,725,572, describes gold plating on the ends of a stent such that the gold plating marks two bands at the ends of a stent. The patentee mentions that the limitation of gold coating is the stiffening of the stent surface. Hence, the gold plating is done only at the ends where the stiffening does not significantly alter the properties of the stent. Also described is another embodiment where only the exterior of the stent is coated with a radiopaque material.</li><li id="ul0002-0003" num="0010">3. U.S. Pat. No. 5,919,126, describes a patent where the body of the stent is formed from a non-radioactive structural material, a radiopaque material coats the body and a beta emitting radioisotope ion is implanted into the radiopaque material.</li><li id="ul0002-0004" num="0011">4. U.S. Pat. No. 5,824,056 describes an implantable medical device formed from a drawn refractory metal having an improved biocompatible surface. The method by which the device is made includes coating a refractory metal article with platinum by a physical vapor deposition process and subjecting the coated article to drawing in a diamond die. The drawn article can be incorporated into an implanted medical device without removing the deposited material.</li><li id="ul0002-0005" num="0012">5. U.S. Pat. No. 5,824,077 describes a stent which is formed of multiple filaments arranged in two sets of oppositely directed helical windings interwoven with each other in a braided configuration. Each of the filaments is a composite including a central core and a case surrounding the core. The core is formed of a radiopaque material while the outer casing is made of a relatively resilient material, e.g., a cobalt, chromium based alloy. Alternative composite filaments described in the patent employ an intermediate barrier layer between the case and the core, a biocompatible cover layer surrounding the case, and a radiopaque case surrounding the central core.</li><li id="ul0002-0006" num="0013">6. U.S. Pat. No. 5,871,437 describes a non-radioactive metallic stent which is coated with a biodegradable or non-biodegradable thin coating of less than about 100 microns in thickness which is selected to avoid provoking any foreign body reaction. This coating contains a radioactive source emitting Beta particles with an activity level of approximately one micro curie and on top of this layer is an anticoagulant substance to inhibit early thrombus formation.</li><li id="ul0002-0007" num="0014">7. U.S. Pat. No. 6,099,561 describes a stent having a biocompatible metal hollow tube constituting a base layer having a multiplicity of openings through an open ended tubular wall thereof, the tube constituting a single member from which the entire stent is fabricated. A thin tightly adherent intermediate layer of noble metal overlies the entire exposed surface area of the tube including edges of the openings as well as exterior and interior surfaces and ends of the wall. A third outermost ceramic like layer composed of an oxide, hydroxide or nitrate of a noble metal is formed atop and in adherent relation to an intermediate layer.</li><li id="ul0002-0008" num="0015">8. U.S. Pat. No. 5,722,984 describes a stent which has an antithrombogenic property and contains an embedded radioisotope that makes the coating material radioactive.</li><li id="ul0002-0009" num="0016">9. Other relevant patents that describe the coating technology or coating properties include U.S. Pat. Nos. 5,818,893; 5,980,974; 5,700,286; 5,858,468; 5,650,202 and U.S. Pat. No. 5,696,714.</li></ul>
Although some of the above mentioned stents have good flexibility and others have good radial strength, there is no optimum stent in the prior art that has both good flexibility and radial strength together with the ability to retain a useful coating.
SUMMARY OF THE INVENTION
The present invention describes a fifth class of stents having multiple designs of structurally variable configuration along the longitudinal length of the stent. The stent has one pattern at both ends of the stent to provide optimal flexibility and a different pattern at the mid-portion of the stent to provide optimal radial strength. Alternatively, the stent has one pattern at each end, a different pattern at its mid-portion and a third pattern in-between the mid-portion and each end. The stent has both closed cell and open cell configuration along its longitudinal length and the closed cells and open cells are interlinked with either straight or wavy configurations in a single stent.
A preferred pattern contains at least three different configurations selected from an open cell design, a closed cell design, a straight interlink or articulation and one wavy interlink or articulation along a variable thickness of connecting stents. Because of the variable thickness of the stents, the amount of drug loaded on the stent is varied along with the release characteristics.
The structurally variable stents of this invention usually have a stainless steel or nickel/titanium alloy (NITINOL®) base material with two layers of coating together not exceeding ten microns in depth. One layer is an undercoat in direct contact with the base metal both on the inside and outside surface of the base metal. The topmost layer is in contact with the blood. Both the undercoat and top coat are of the same material such as metallic, biological, synthetic material, or polymeric material.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention can be best understood by those having ordinary skill in the art by reference to the following detailed description when considered in conjunction with the accompanying drawings in which:
<figref idref="DRAWINGS">FIG. 1</figref> shows a closed cell design of a stent.
<figref idref="DRAWINGS">FIG. 2</figref> shows a closed cell design of a stent interconnected by a straight bridge.
<figref idref="DRAWINGS">FIG. 3</figref> shows an exterior design of a closed cell stent.
<figref idref="DRAWINGS">FIG. 4</figref> shows a design of an open cell stent with a radiopaque coating on one section of the stent.
<figref idref="DRAWINGS">FIG. 5</figref> shows a design of a coil stent.
<figref idref="DRAWINGS">FIG. 6</figref> shows a design of a structurally variable stent having an open cell design on the ends and a closed cell design at the center of the stent.
<figref idref="DRAWINGS">FIG. 7</figref> shows a design of a structurally variable stent with variable thickness of the open and closed cell design.
<figref idref="DRAWINGS">FIG. 8</figref> shows a design of a structurally variable stent with open cell at the ends and closed cell at the mid-portion and alternating articulations between both the open and closed cell.
<figref idref="DRAWINGS">FIG. 9</figref> shows a design of a structurally variable stent with both open and closed cell design and the articulations at the end of the closed cell design is an S-shape rather than a W-shape.
<figref idref="DRAWINGS">FIG. 10</figref> shows a design of a structurally variable stent with both open and closed cell design and alternating articulations at various sections of the stent.
<figref idref="DRAWINGS">FIG. 11</figref> shows a design of a structurally variable stent with an open cell design at the ends with multiple S-shapes and a straight articulating member and closed cell design and the mid-portion with a complex plus sign articulation.
<figref idref="DRAWINGS">FIG. 12</figref> shows a design of a structurally variable stent with a circle at a mid-portion of the open cell design.
<figref idref="DRAWINGS">FIG. 13</figref> shows a design of a structurally variable stent with different wall thickness along the length of the stent.
<figref idref="DRAWINGS">FIG. 14</figref> shows a cross sectional view on a portion of the structurally variable stent including two coating layer.
DETAILED DESCRIPTION OF THE INVENTION
Throughout the following detailed description the same reference numerals refer to the same elements in all figures.
Referring to <figref idref="DRAWINGS">FIG. 1</figref>, the closed cell tubular stent design <b>10</b> has a longitudinal series of cells <b>12</b>. As seen in <figref idref="DRAWINGS">FIG. 2</figref>, the cells <b>12</b> are interconnected by a bridge <b>14</b>. The exterior look of such a stent <b>10</b> is seen in FIG. <b>3</b>. In contrast, <figref idref="DRAWINGS">FIG. 4</figref> shows the design of an open cell stent <b>16</b> having multiple open cells <b>18</b>. One section <b>20</b> of the open cell stent <b>16</b> has a radiopaque coating <b>22</b>.
A coil stent <b>24</b> design is shown in FIG. <b>5</b>.
Referring to <figref idref="DRAWINGS">FIG. 6</figref>, the stent <b>26</b> of this invention is shown. The stent <b>26</b> has an open cell <b>16</b> configuration at each end and a closed cell design <b>10</b> at the center portion of the stent <b>26</b>. Connecting struts <b>28</b> join the components.
The stent <b>26</b>A shown in <figref idref="DRAWINGS">FIG. 7</figref> has the same configuration as stent <b>26</b> shown in <figref idref="DRAWINGS">FIG. 6</figref>, except that the thickness of the structure varies. The articulations <b>30</b> in a W-pattern are all the same. In <figref idref="DRAWINGS">FIG. 8</figref>, in contrast, articulations <b>32</b> are in the shape of an S-pattern while other articulations <b>30</b> remain in the W-pattern.
In <figref idref="DRAWINGS">FIG. 9</figref>, the stent <b>26</b>B has a closed cell design <b>10</b> at its mid-portion and an open cell design <b>16</b> at each end. The articulations <b>32</b> are all in the shape of an S-pattern. In <figref idref="DRAWINGS">FIG. 10</figref>, the stent <b>26</b>C has a closed cell design <b>10</b> at its mid-portion and an open cell design <b>16</b> at each end, but with alternating S-pattern <b>32</b> and W-pattern <b>30</b> articulations.
In <figref idref="DRAWINGS">FIG. 11</figref>, the stent <b>26</b>D has an open cell design <b>16</b> at its ends in an S-pattern, a straight articulating member <b>34</b>, a closed cell <b>10</b> mid-portion with a complex plus sign pattern articulation <b>36</b>.
In <figref idref="DRAWINGS">FIG. 12</figref>, the stent <b>26</b>E has an open cell design <b>16</b> at its ends with a circle <b>38</b> in the open cell design. The center portion is a closed cell design <b>10</b>.
In <figref idref="DRAWINGS">FIG. 13</figref>, the stent <b>26</b>F has thick <b>40</b> and thin <b>42</b> wall thickness.
The combination of an open cell <b>16</b> and closed cell <b>10</b> stent design creates a stent having both flexibility and radial strength along the length of the stent. The variable stent thickness <b>40</b> and <b>42</b> provides greater functional properties for coating the stent. If the coating is to enhance the radio opacity, then the ends can be made more radiopaque than the mid-portion. If the objective of a coating is to load more drugs then the ends of the stein can be thicker to allow for such coating. Since restenosis occurs in a stent invariably at its ends, a higher drug concentration at the ends can more thoroughly inhibit such restenosis.
The thickness of the open cell design <b>16</b> versus the closed cell design <b>10</b> may vary as seen in the drawings. The open cell design <b>16</b> is generally twenty-five percent thicker than the mid-portion or closed cell design <b>10</b>.
Referring to <figref idref="DRAWINGS">FIG. 14</figref> it is preferred to have two layers of coatings on the entire length of the stent <b>26</b>. A base coat <b>44</b> of metal and a top coat <b>46</b> of metal enhances radio opacity of the stent <b>26</b>. Abase coat <b>44</b> of a polymeric coating has a top coat <b>46</b> of a drug which slowly diffuses out of the stent <b>26</b> over a period of time. The variable design stents <b>26</b>-<b>26</b>F of this invention allows the loading of drugs at the ends to facilitate a graded release profile.
The stents <b>26</b>-<b>26</b>F of this invention are longitudinal, cylindrical, metal structures having at least an open cell and closed cell design joined together by struts. The metal can be nickel-titanium alloy (NITINOL®) titanium, stainless steel or a noble base metal. A coating of at least two layers over the base metal has a depth not to exceed ten microns.
Typical coatings are set forth in U.S. Pat. Nos. 5,759,174; 5,725,572; 5,824,056; and 5,871,437 and are herein incorporated by reference.
The above description has described specific structural details embodying the variable stents of this invention. However, it will be within the skill of one having ordinary skill in the art to make modifications without departing from the spirit and scope of the underlying inventive concept of these structurally variable stents.
Contents4
9 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| US7862495B2 | Cited by | United States of America | Search report |
| US11714213B2 | Cited by | United States of America | Applicant |
| US7297157B2 | Cited by | United States of America | Search report |
| US10837103B2 | Cited by | United States of America | Applicant |
| CN102302389A | Cited by | China | Search report |
| US11231526B2 | Cited by | United States of America | Applicant |
| US10995404B2 | Cited by | United States of America | Applicant |
| US2003225451A1 | Cited by | United States of America | Pre-grant |
| US2010174360A1 | Cited by | United States of America | Pre-grant |
| WO2007002685A2 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| US2007190231A1 | Cited by | United States of America | Pre-grant |
| US11698475B2 | Cited by | United States of America | Applicant |
| US8974514B2 | Cited by | United States of America | Applicant |
| US11002885B2 | Cited by | United States of America | Applicant |
| US11667565B2 | Cited by | United States of America | Applicant |
| US8298147B2 | Cited by | United States of America | Applicant |
| US10948629B2 | Cited by | United States of America | Applicant |
| US11267973B2 | Cited by | United States of America | Applicant |
| US2002183581A1 | Cited by | United States of America | Pre-grant |
| US2007038061A1 | Cited by | United States of America | Pre-grant |
| US7682649B2 | Cited by | United States of America | Applicant |
| US2008228261A1 | Cited by | United States of America | Pre-grant |
| WO2007002685A3 | Cited by | World Intellectual Property Organization (WIPO) | International search |
| US2004068315A1 | Cited by | United States of America | Pre-grant |
| US5650202A | Cites | United States of America | Applicant |
| US5695714A | Cites | United States of America | Applicant |
| US5700286A | Cites | United States of America | Applicant |
| US5722984A | Cites | United States of America | Applicant |
| US5800511A | Cites | United States of America | Applicant |
| US5824056A | Cites | United States of America | Applicant |
| US5824077A | Cites | United States of America | Applicant |
| US5858468A | Cites | United States of America | Applicant |
| US5871437A | Cites | United States of America | Applicant |
| US5911754A | Cites | United States of America | Applicant |
| US5919126A | Cites | United States of America | Applicant |
| US5980974A | Cites | United States of America | Applicant |
| US6099561A | Cites | United States of America | Applicant |
| US6146417A | Cites | United States of America | Applicant |
| US6161399A | Cites | United States of America | Applicant |
| US6162245A | Cites | United States of America | Applicant |
| US6174329B1 | Cites | United States of America | Applicant |
| US6375677B1 | Cites | United States of America | Search report |
| US6540775B1 | Cites | United States of America | Applicant |
45 members in 12 offices
Priority claims2
| Document | Office | Kind | Date |
|---|---|---|---|
| 94132701 | United States of America | A | |
| US20010941327 | – | – | – |
Members45
| Document | Office | Kind | |
|---|---|---|---|
| CA2390938A1 | Canada | A1 | |
| WO0135859A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU1403401A | Australia | A | |
| EP1229862A1 | European Patent Office (EPO) | A1 | |
| US6475235B1 | United States of America | B1 | |
| IL149609D0 | Israel | D0 | |
| HK1045093A1 | Hong Kong, China | A1 | |
| US2003045925A1 | United States of America | A1 | |
| US2003055479A1 | United States of America | A1 | |
| JP2003513746A | Japan | A | |
| US2003099712A1 | United States of America | A1 | |
| CA2468254A1 | Canada | A1 | |
| WO03045523A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU2002362015A1 | Australia | A1 | |
| WO03045523A3 | World Intellectual Property Organization (WIPO) | A3 | |
| US6641611B2 | United States of America | B2 | |
| US6746478B2 | United States of America | B2 | |
| US2004137066A1 | United States of America | A1 | |
| EP1448281A2 | European Patent Office (EPO) | A2 | |
| AU780715B2 | Australia | B2 | |
| JP2005510315A | Japan | A | |
| US6908480B2This record | United States of America | B2 | |
| US2006004437A1 | United States of America | A1 | |
| EP1448281A4 | European Patent Office (EPO) | A4 | |
| US2006224234A1 | United States of America | A1 | |
| WO2007002133A2 | World Intellectual Property Organization (WIPO) | A2 | |
| EP1229862B1 | European Patent Office (EPO) | B1 | |
| IL149609A | Israel | A | |
| AT353607T | Austria | T | |
| DE60033417D1 | Germany | D1 | |
| WO2007002133A3 | World Intellectual Property Organization (WIPO) | A3 | |
| AU2002362015B2 | Australia | B2 | |
| WO2007118139A2 | World Intellectual Property Organization (WIPO) | A2 | |
| DE60033417T2 | Germany | T2 | |
| WO2007118139A3 | World Intellectual Property Organization (WIPO) | A3 | |
| DE112006001665T5 | Germany | T5 | |
| CN101237833A | China | A | |
| WO2007118139A9 | World Intellectual Property Organization (WIPO) | A9 | |
| JP2008546484A | Japan | A | |
| EP1448281B1 | European Patent Office (EPO) | B1 | |
| AT422909T | Austria | T | |
| DE60231231D1 | Germany | D1 | |
| DK1448281T3 | Denmark | T3 | |
| CA2390938C | Canada | C | |
| CA2468254C | Canada | C |
50 transactions on the USPTO file
Allowed after 1 non-final rejection and 1 final rejection.
- Non-final rejections
- 1
- Final rejections
- 1
- RCEs
- 0
- Appeals
- 0
Over time
Point at a mark for the transactionTransactions
| Event | |
|---|---|
| Expire Patent | |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | |
| Post Issue Communication - Certificate of Correction | |
| Recordation of Patent Grant Mailed | |
| Patent Issue Date Used in PTA CalculationAllowed | |
| Issue Notification MailedAllowed | |
| Receipt into Pubs | |
| Dispatch to FDC | |
| Dispatch to FDC | |
| Application Is Considered Ready for Issue | |
| Workflow - Drawings Finished | |
| Issue Fee Payment Verified | |
| Issue Fee Payment Received | |
| Receipt into Pubs | |
| Workflow - File Sent to Contractor | |
| Mail Notice of AllowanceAllowed | |
| Notice of Allowance Data Verification CompletedAllowed | |
| Date Forwarded to Examiner | |
| Response after Final Action | |
| Mail Final Rejection (PTOL - 326)Final rejection | |
| Final RejectionFinal rejection | |
| Date Forwarded to Examiner | |
| Response to Election / Restriction Filed | |
| Workflow incoming amendment IFW | |
| Mail Restriction Requirement | |
| Restriction/Election Requirement | |
| IFW TSS Processing by Tech Center Complete | |
| Date Forwarded to Examiner | |
| Mail Examiner Interview Summary (PTOL - 413) | |
| Response after Non-Final Action | |
| Interview Summary Record | |
| Mail Non-Final RejectionNon-final rejection | |
| Non-Final RejectionNon-final rejection | |
| Date Forwarded to Examiner | |
| Electronic Information Disclosure Statement | |
| Information Disclosure Statement (IDS) Filed | |
| Electronic Information Disclosure Statement | |
| Information Disclosure Statement (IDS) Filed | |
| Response to Election / Restriction Filed | |
| Mail Restriction Requirement | |
| Restriction/Election Requirement | |
| Correspondence Address Change | |
| Change in Power of Attorney (May Include Associate POA) | |
| Case Docketed to Examiner in GAU | |
| Application Dispatched from OIPE | |
| Correspondence Address Change | |
| Information Disclosure Statement (IDS) Filed | |
| Information Disclosure Statement (IDS) Filed | |
| IFW Scan & PACR Auto Security Review | |
| Initial Exam Team nn |
9 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Lapsed due to failure to pay maintenance feeLapsedFP | FP | |
| Information on status: patent discontinuationPATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362STCH | STCH | |
| Lapse for failure to pay maintenance feesLapsedLAPS | LAPS | |
| Maintenance fee reminder mailedREMI | REMI | |
| Fee paymentFPAY | FPAY | |
| Fee paymentFPAY | FPAY | |
| Fee payment procedurePAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITYFEPP | FEPP | |
| AssignmentAS | AS | |
| Certificate of correctionCC | CC |
Numbers
- Publication
- 06908480
- Publication, DOCDB
- 6908480
- Publication, EPODOC
- US6908480
- Application
- 9941327
- Application, DOCDB
- 94132701
- Application, EPODOC
- US20010941327
Titles
- English
- Structurally variable stents
Patent term adjustment
- A delay
- +332 daysthe office missed an examination deadline
- Applicant delay
- −42 days
- Net adjustment
- 290 days
Classification
- CPC, 8
- A61F2/91
- A61F2/915
- A61F2002/91525
- A61F2002/91533
- A61F2002/91558
- A61F2002/91575
- A61F2230/0013
- A61F2230/0054
- IPC, 2
- A61F2 06
- A61F2 90
- USPC, 2
- 623001420
- 623001460